Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_1
2
50%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(1)
Other(2)

Detailed Status

unknown2
Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

terminated125%
completed125%
unknown250%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_1

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

NCT03650764
unknown

Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Molecular Testing Panel in the Community Setting ("DINOSAur")

NCT05692466
unknown

Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Liquid Molecular Testing Panel in the Community Setting ("DINOSAur II")

NCT05703243
terminatedphase_1

Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

NCT03655444

Clinical Trials (4)

Showing 4 of 4 trials
NCT03650764Phase 1

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Completed
NCT05692466

Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Molecular Testing Panel in the Community Setting ("DINOSAur")

Unknown
NCT05703243

Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Liquid Molecular Testing Panel in the Community Setting ("DINOSAur II")

Unknown
NCT03655444Phase 1

Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

Terminated

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4